Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Rheumatology International
Erschienen in: Rheumatology International 1/2018

20.10.2017 | Comorbidities

Cardiac disease in familial Mediterranean fever

verfasst von: Eren Erken, Ertugrul Erken

Erschienen in: Rheumatology International | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Familial Mediterranean fever (FMF) is an autoinflammatory disease manifested by inflammatory attacks of peritonitis, pleuritis, pericarditis accompanied by fever and arthritis. Mutations of MEFV gene results in pyrin dysfunction, which causes uncontrolled interleukin-1 beta production and triggers the inflammatory attacks. Inflammation persists even during attack-free periods in one-third of the FMF patients. Findings of elevated proinflammatory cytokine patterns during remission as well as inflammatory attacks indicate the continuous subclinical disease activity and inflammation. Chronic inflammation was thought to be related to the cardiovascular risk in FMF patients. Main cardiac manifestations reported in FMF are pericarditis, idiopathic recurrent pericarditis, pericardiac tamponade, coronary heart disease and abnormal cardiovascular reactivity. Cardiac involvement in FMF may often be related to secondary AA amyloidosis. Deposition of amyloid may lead to cardiovascular morbidity and mortality in FMF patients. Associations of several vasculitic disorders such as Immunoglobulin A-associated vasculitis, polyarteritis nodosa and Behcet’s disease are common in FMF. Appropriate prophylactic treatment with colchicine is recommended to prevent from cardiovascular risks. For those resistant to colchicine, IL-1 inhibitor agents can be used. Associated vasculitis should be treated with immunosuppressive agents. This review article aims to compile information about cardiac disease in FMF and refer to recent studies on the topic.
Literatur
1.
Shohat M, Halpern GJ (2011) Familial Mediterranean fever—a review. Genet Med 13(6):487–498PubMedCrossRef
2.
3.
Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12:14–17PubMedCrossRef
4.
Twig G, Livneh A, Vivante A et al (2014) Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 73:704–709PubMedCrossRef
5.
Twig G, Livneh A, Vivante A et al (2014) Cardiovascular and metabolic risk factors in inherited autoinflammation. J Clin Endocrinol Metab 99:E2123–E2128PubMedCrossRef
6.
Akar S, Yuksel F, Tunca M et al (2012) Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine (Baltimore) 91:131–136CrossRef
7.
Braun J, Krüger K, Manger B et al (2017) Cardiovascular comorbidity in inflammatory rheumatological conditions. Dtsch Arztebl Int 114:179–203
8.
Rigante D, Cantarini L, Imazio M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43:341–346PubMedCrossRef
9.
Tunca M, Akar S, Onen F et al (2005) Familial Mediterranean fever (FMF) in Turkey. Results of a nationwide multicenter study. Medicine 84:1–11PubMedCrossRef
10.
11.
Yildiz A, Akkaya V, Kiliçaslan I et al (2001) Cardiac and intestinal amyloidosis in a renal transplant recipient with familial Mediterranean fever. J Nephrol 14:125–127PubMed
12.
Nussinovitch U, Volovitz B, Nussinovitch M et al (2011) Abnormal heart rate variability in AA amyloidosis of familial Mediterranean fever. Amyloid 18(4):206–210PubMedCrossRef
13.
Ambartsymian SV (2012) Morphological aspects of the familial Mediterranean fever. Ga Med News 3(204):59–61
14.
Ambartsymian SV (2012) Myocardial infarction in patients with familial Mediterranean fever and cardiac lesions. Ga Med News 3(204):62–64
15.
Erdem H, Simsek I, Pay S et al (2006) Diffuse pulmonary amyloidosis that mimics interstitial lung disease in a patient with familial Mediterranean fever. JCR 12(1):34–36PubMed
16.
Johnson WJ, Lie JT (1991) Pulmonary hypertension and familial Mediterranean fever: a previously unrecognized association. Mayo Clin Proc 66:919–925PubMedCrossRef
17.
Yilmaz MI, Demirkaya E, Acikel C et al (2014) Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. Rheumatology 53:2002–2008PubMedCrossRef
18.
Kees S, Langevitz P, Zemer D et al (1997) Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). Q J Med 90:643–647CrossRef
19.
Zimand S, Tauber T, Hegesh T et al (1994) Familial Mediterranean fever presenting cardiac tamponade. Clin Exp Rheumatol 12:67–69PubMed
20.
Yoshioka K, Furumitsu Y, Sano T et al (2014) Acute pericarditis as the first manifestation of familial Mediterranean fever: possible relationship with idiopathic recurrent pericarditis. Intern Med 53:1659–1663PubMedCrossRef
21.
Sanchez Ferrer F, Martinez Villar M, Fernendez Bellar A et al (2015) Cardiac tamponade as first manifestation in Mediterranean fever with autosomal dominant form. An Pediatr (Barc) 82(1):e82–e85CrossRef
22.
Rozenbaum M, Naschitz JE, Yudashkin M et al (2002) Cardiovascular autonomic dysfunction in familial Mediterranean fever. J Rheumatol 29:987–989PubMed
23.
Canpolat U, Dural M, Aytemir K et al (2012) Evaluation of various cardiac autonomic indices in patients with familial Mediterranean fever on colchicine treatment. Auton Neurosci 167:70–74PubMedCrossRef
24.
Nussinovitch N, Esev K, Lidar M et al (2015) Normal heart rate variability in colchicine-resistant familial Mediterranean fever patients. IMAJ 17:306–309PubMed
25.
Nussinovitch N, Livneh A, Katz K et al (2011) Heart rate variability in familial Mediterranean fever. Rheumatol Int 31:39–43PubMedCrossRef
26.
Nussinovitch U, Livneh A, Volovitz B et al (2012) Normal QT dispersion in colchicine-resistant familial Mediterranean fever. Clin Rheum 31:1093–1096CrossRef
27.
Nussinovitch U, Kaminer K, Nussinovitch M et al (2012) QT interval variability in familial Mediterranean fever: a study in colchicine responsive and colchicine resistant patients. Clin Rheum 31:795–799CrossRef
28.
Akcay A, Acar G, Sayarlioglu M et al (2009) QT dispersion and transmural dispersion of repolarization in patients with familial Mediterranean fever. Mod Rheumatol 19(5):550–555PubMedCrossRef
29.
Karaman K, Karayakali M, Erken E et al (2017) Assessment of myocardial repolarisation parameters in patients with familial Mediterranean fever. Cardiovasc J Afr 28(3):154–158PubMedPubMedCentralCrossRef
30.
Nussinovitch U, Nussinovitch N, Nussinovitch M et al (2012) QT dispersion in amyloidosis due to familial Mediterranean fever. Rheumatol Int 32:1945–1948PubMedCrossRef
31.
Koca B, Kasapçopur O, Bakari S et al (2012) QT dispersion and cardiac involvement in children with Familial Mediterranean fever. Cardiol Young 22(4):404–409PubMedCrossRef
32.
Nussinovitch N, Livneh A, Katz K et al (2011) P wave dispersion in familial Mediterranean fever. Rheumatol Int 31:1591–1594PubMedCrossRef
33.
Gang N, Drenth JP, Langevitz P et al (1999) Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26:890–896PubMed
34.
Kiraz S, Ertenli I, Arici M et al (1998) Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 16:721–724PubMed
35.
Bagci S et al (2004) Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 23:333–337PubMedCrossRef
36.
Erken E, Ozer HT, Bozkurt B et al (2008) Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Jt Bone Spine 75(3):370–372CrossRef
37.
Erken E, Ozer HT, Gunesacar R (2006) Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever. Rheumatol Int 26(9):862–864PubMedCrossRef
38.
Direskeneli H, Ozdogan H, Korkmaz C et al (1999) Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol 26(9):1983–1986PubMed
39.
Simsek I, Pay S, Pekel A et al (2007) Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int 27(9):807–811PubMedCrossRef
40.
Aksu K, Keser G (2011) Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int 31:1263–1274PubMedCrossRef
41.
Yuksel S, Ayvazyan L, Gasparyan AY (2010) Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 4:51–56PubMedPubMedCentral
42.
Akdogan A, Calguneri M, Yavuz B et al (2006) Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 48:2351–2353PubMedCrossRef
43.
Yildiz M, Masatlioglu S, Seymen P et al (2006) The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever. Can J Cardiol 22:1127–1131PubMedPubMedCentralCrossRef
44.
Terekeci HM, Oktenli C, Ozgurtas T et al (2008) Increased asymmetric dimethyl arginine levels in young man with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 35:2024–2029PubMed
45.
Bilginer Y, Ozaltin F, Basaran C et al (2008) Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 28:1211–1216PubMedCrossRef
46.
Peru H, Altun B, Doğan M et al (2008) The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 27:689–694PubMedCrossRef
47.
Sari I, Karaoglu O, Can G et al (2007) Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 26:1467–1473PubMedCrossRef
48.
Caliskan M, Gullu H, Yilmaz S et al (2007) Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 195(2):e161–e167PubMedCrossRef
49.
Langevitz P, Livneh A, Neumann L et al (2001) Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 3(1):9–12PubMed
50.
Aksu G, Ozturk C, Kavakli K et al (2007) Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol 26:366–370PubMedCrossRef
51.
Demirel A, Celkan T, Kasapcopur O et al (2008) Is Familial Mediterranean Fever a thrombotic disease or not? Eur J Pediatr 167:279–285PubMedCrossRef
52.
Rabinovich E, Shinar Y, Leiba Y et al (2007) Common FMF alleles may predispose to development of Behcet’s disease with increased risk for venous thrombosis. Scand J Rheumatol 36:48–52PubMedCrossRef
53.
Aoun EG, Musallam KM, Uthman I et al (2009) Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus 18:845–847PubMedCrossRef
54.
Ustundag Y, Bayraktar Y, Emri S (1998) Superior vena cava thrombosis and obstructive sleep apnea in a patient with familial Mediterranean fever. Am J Med Sci 316(1):53–55PubMedCrossRef
55.
Ruiz XD, Gadea CM (2011) Familial Mediterranean fever presenting with pulmonary embolism. Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients. Conn Med 75(1):17–19PubMed
56.
Reuben A, Hirsch M, Berlyne GM (1977) Renal vein thrombosis as the major cause of renal failure in familial Mediterranean fever. Q J Med 46(182):243–258PubMed
57.
Serrano R, Martinez MA, Andres A et al (1998) Familial Mediterranean fever and acute myocardial infarction secondary to coronary vasculitis. Histopathology 33:163–167PubMedCrossRef
58.
Cocco G (2008) Vasculitis, left bundle block, and Raynaud’s phenomenon as a manifestation of familial Mediterranean fever. Arch Med Sci 4:460–464
59.
Peleg H, Ben-Chetrit E (2017) Vasculitis in the autoinflammatory diseases. Curr Opin Rheumatol 29(1):4–11PubMedCrossRef
60.
Gershoni-Baruch R, Broza Y, Brick R (2003) Prevalance and significance of mutations in the familial Mediterranean fever gene in Henoch–Schönlein purpura. J Pediatr 143:648–661CrossRef
61.
Ozcakar ZB, Yalcinkaya F, Cakar N et al (2008) MEFV mutations modify the clinical presentation of Henoch–Schönlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef
62.
Ozdogan H, Arisoy N, Kasapcopur O et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed
63.
Yalcinkaya F, Ozcakar B, Kasapcopur O et al (2007) Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. J Pediatr 151:675–678PubMedCrossRef
64.
Ozen S, Ben-Chetrit E, Bakkaloglu A et al (2001) Polyarteritis nodosa in patients with familial Mediterranean fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum 30:281–287PubMedCrossRef
65.
Schwartz T, Langevitz B, Zemer D (1997) Behcet’s disease in familial Mediterranean fever: characterization of the association between two diseases. In: Sohar E, Gafni J, Pras M (eds) Familial Mediterranean fever. Freund Publishing House, Tel-Aviv, pp 148–150
66.
Ben-Chetrit E, Cohen R, Chajek-Saul T (2002) Familial Mediterranean fever and Behcet’s disease—are they associated? J Rheumatol 29:530–534PubMed
67.
Touitou I, Magne X, Molinari N et al (2000) MEFV mutations in Behcet’s disease. Hum Mutat 16(3):271–272PubMedCrossRef
68.
Ozturk MA, Kanbay M, Kasapoglu B et al (2011) Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 29(Suppl. 67):77–86
69.
Wu B, Xu T, Li Y, Yin X (2015) Interventions for reducing inflammation in familial Mediterranean fever (review). Cochrane Database Syst Rev 20(3):CD010893 (1–40)
70.
Gasparyan AY, Ayvazyan L, Yessirkepov M et al (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11(11):1781–1794PubMedCrossRef
71.
Zemer D, Pras M, Sohar E et al (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005PubMedCrossRef
72.
Adler Y, Finkelstein Y, Guindo J et al (1998) Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation 97(21):2183–2185PubMedCrossRef
73.
Lotan D, Wasserstrum Y, Fardman A et al (2016) Usefulness of novel immunotherapeutic strategies for idiopathic recurrent pericarditis. Am J Cardiol 117(5):861–866PubMedCrossRef
74.
Grattagliano I, Bonfrate L, Ruggiero V et al (2014) Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95(1):89–97PubMedCrossRef
75.
Gul A (2016) Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol 30:296–303PubMedCrossRef
76.
van der Hilst J, Moutschen M, Messiaen PE et al (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75e80
77.
Hamanoue S, Suwabe T, Hoshino J et al (2016) Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol 26(4):610–613PubMed
78.
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP et al (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449PubMedCrossRef
Metadaten
Titel
Cardiac disease in familial Mediterranean fever
verfasst von
Eren Erken
Ertugrul Erken
Publikationsdatum
20.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 1/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3853-8

Weitere Artikel der Ausgabe 1/2018

Rheumatology International 1/2018 Zur Ausgabe

Case Based Review

Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab

Genes and Disease

MMAB, a novel candidate gene to be screened in the molecular diagnosis of Mevalonate Kinase Deficiency

Genes and Disease

Evidence for genetic overlap between adult onset Still’s disease and hereditary periodic fever syndromes

Genes and Disease

One novel and two uncommon MEFV mutations in Japanese patients with familial Mediterranean fever: a clinicogenetic study

Food for Thought

Short-term application of tocilizumab during myocardial infarction (STAT-MI)

Observational Research

Fatigue in familial Mediterranean fever and its relations with other clinical parameters

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise